Pomalidomide

The FDA granted accelerated approval to pomalidomide for treatment of two forms of Kaposi sarcoma.

March is Myeloma Awareness Month.

Approximately one-quarter of patients with triple-class refractory multiple myeloma responded to treatment with melflufen, according to final topline results from the pivotal phase 2 HORIZON study released by the agent’s manufacturer.

Low-dose pomalidomide was well-tolerated and helped clear high-grade squamous intraepithelial lesions caused by HPV in patients with and without HIV, according to research from the Conference on Retroviruses and Opportunistic Infections.

The FDA approved isatuximab-irfc in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who received at least two previous therapies, including lenalidomide and a proteasome inhibitor.